Overview

Price chart · mood · technical indicators

PRPO

Precipio Incstock Healthcare

Diagnostics & Research

$29.70378.57%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$5.94$32.40

Current: $29.70

Idea: EMA

1Y Return

+294.1%

Sharpe 3Y

0.58

Market Comparison

vs Healthcare Sector & Diagnostics & Research Industry

PRPO

+378.57%

1Y Performance

Healthcare

Sector 1Y

Diagnostics & Research

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio—Forward 15.43

EPS (TTM)$-0.230.0% YoY

Profit margin-1.5%HEALTHCARE

Market cap$55.2MMicro cap

Valuation

Forward P/E: 15.43
PEG ratio: 0.00
P/B: 3.79
P/S (TTM): 2.30
EV/EBITDA: 38.46

Profitability & growth

ROE (TTM): -2.7%
Operating margin: 8.1%
Revenue growth YoY: 22.9%
Dividend yield: —
Beta: 1.38

Last earnings

Apr 2, 2026 · Reported $0.30

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Precipio Inc

Company profile

Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.

Classification

Sector: Healthcare
Industry: Diagnostics & Research
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 4 SCIENCE PARK, NEW HAVEN, CT
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$55.2M

Shares outstanding$1.8M

52W high$32.40

52W low$5.94

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

PRPO

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

[ARS] Precipio, Inc. SEC Filing

How (PRPO) Movements Inform Risk Allocation Models

Board member for Precipio (NASDAQ: PRPO) receives 93-share grant

Precipio (PRPO) director paid in stock grant for Q1 board service

Stock grant lifts Precipio (PRPO) director Cossman to 16,133 shares

Trading Systems Reacting to (PRPO) Volatility

Precipio COO Sabet Ahmed Zaki buys $530 in PRPO stock

Precipio (PRPO) COO buys shares under 10b5-1 trading plan

PRPO Price Today: Precipio, Inc. Stock Price, Quote & Chart

How Precipio Inc. (PRPO) Affects Rotational Strategy Timing

If You Invested $1,000 in Precipio Inc (PRPO)

(PRPO) and the Role of Price-Sensitive Allocations

PRPO SEC Filings - Precipio Inc 10-K, 10-Q, 8-K Forms

CapEx per share of Precipio, Inc. – MUN:TGK

Cancer diagnostics firm Precipio sets April 2 call on 2025 progress

Topline Capital Management LLC Purchases New Holdings in Precipio, Inc. $PRPO

Precipio (NASDAQ:PRPO) Stock Rating Upgraded by Wall Street Zen

Precipio, Inc. to Host Q4 and Year-End 2025 Corporate Update Call on April 2, 2026

Precipio and Memorial Sloan-Kettering Publish Study on BCR::ABL1 Assay for Leukemia Monitoring

Responsive Playbooks and the PRPO Inflection

About Precipio Inc

Classification

Company profile

PRPO

Market Comparison

PRPO Market Analysis

Overview

PRPO

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

[ARS] Precipio, Inc. SEC Filing

How (PRPO) Movements Inform Risk Allocation Models

Board member for Precipio (NASDAQ: PRPO) receives 93-share grant

Precipio (PRPO) director paid in stock grant for Q1 board service

Stock grant lifts Precipio (PRPO) director Cossman to 16,133 shares

Trading Systems Reacting to (PRPO) Volatility

Precipio COO Sabet Ahmed Zaki buys $530 in PRPO stock

Precipio (PRPO) COO buys shares under 10b5-1 trading plan

PRPO Price Today: Precipio, Inc. Stock Price, Quote & Chart

How Precipio Inc. (PRPO) Affects Rotational Strategy Timing

If You Invested $1,000 in Precipio Inc (PRPO)

(PRPO) and the Role of Price-Sensitive Allocations

PRPO SEC Filings - Precipio Inc 10-K, 10-Q, 8-K Forms

CapEx per share of Precipio, Inc. – MUN:TGK

Cancer diagnostics firm Precipio sets April 2 call on 2025 progress

Topline Capital Management LLC Purchases New Holdings in Precipio, Inc. $PRPO

Precipio (NASDAQ:PRPO) Stock Rating Upgraded by Wall Street Zen

Precipio, Inc. to Host Q4 and Year-End 2025 Corporate Update Call on April 2, 2026

Precipio and Memorial Sloan-Kettering Publish Study on BCR::ABL1 Assay for Leukemia Monitoring

Responsive Playbooks and the PRPO Inflection

About Precipio Inc

Classification

Company profile

PRPO

Market Comparison